FSBI of higher education"Ogarev Mordovia State University"
Welcome,         Profile    Billing    Logout  
 5 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Skopin, Pavel
UNIVERSE, NCT06640530: Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® As Monotherapy in Subjects with Advanced Melanoma of the Skin

Recruiting
3
392
RoW
BCD-263, Nivolumab, Opdivo
Biocad
Advanced Melanoma, Melanoma (Skin)
12/25
03/27
OCTAVA, NCT05732805: A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma

Active, not recruiting
3
270
RoW
BCD-217, nurulimab+prolgolimab, BCD-100, prolgolimab, Forteca, Placebo
Biocad
Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV, Melanoma Unresectable, Melanoma Metastatic, Melanoma Advanced
06/24
07/25
FERMATA, NCT03912415 / 2019-000623-40: Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer

Recruiting
3
316
RoW
BCD-100, Bevacizumab, Paclitaxel, Cisplatin (or Carboplatin), Placebo
Biocad
Cervical Cancer
12/24
12/24
NEO-MIMAJOR, NCT05751928: A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma

Recruiting
3
410
RoW
BCD-217, nurulimab+prolgolimab, anti-PD1, Excision of the primary lesion, Regional lymphadenectomy
Biocad
Melanoma Stage III, Melanoma (Skin)
01/27
06/27
NCT06112808: A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin

Recruiting
1
300
RoW
BCD-263, Nivolumab, Opdivo
Biocad
Advanced Melanoma
09/24
01/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Skopin, Pavel
UNIVERSE, NCT06640530: Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® As Monotherapy in Subjects with Advanced Melanoma of the Skin

Recruiting
3
392
RoW
BCD-263, Nivolumab, Opdivo
Biocad
Advanced Melanoma, Melanoma (Skin)
12/25
03/27
OCTAVA, NCT05732805: A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma

Active, not recruiting
3
270
RoW
BCD-217, nurulimab+prolgolimab, BCD-100, prolgolimab, Forteca, Placebo
Biocad
Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV, Melanoma Unresectable, Melanoma Metastatic, Melanoma Advanced
06/24
07/25
FERMATA, NCT03912415 / 2019-000623-40: Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer

Recruiting
3
316
RoW
BCD-100, Bevacizumab, Paclitaxel, Cisplatin (or Carboplatin), Placebo
Biocad
Cervical Cancer
12/24
12/24
NEO-MIMAJOR, NCT05751928: A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma

Recruiting
3
410
RoW
BCD-217, nurulimab+prolgolimab, anti-PD1, Excision of the primary lesion, Regional lymphadenectomy
Biocad
Melanoma Stage III, Melanoma (Skin)
01/27
06/27
NCT06112808: A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin

Recruiting
1
300
RoW
BCD-263, Nivolumab, Opdivo
Biocad
Advanced Melanoma
09/24
01/27

Download Options